Logo

Alvotech’s AVT02 (biosimilar, adalimumab) Receives EC’s Approval for the Treatment of Autoimmune Disease

Share this

Alvotech’s AVT02 (biosimilar, adalimumab) Receives EC’s Approval for the Treatment of Autoimmune Disease

Shots:

 

  • The EC has granted marketing authorization for Alvotech’s adalimumab biosimilar AVT02 to reference Humira. In Sept., the product received a recommendation for approval from the EMA’s CHMP includes all EU Member States along with countries in the EEA, Iceland, Liechtenstein, and Norway
  • AVT02 is a high concentration biosimilar to Humira (adalimumab) which is used for autoimmune and inflammatory conditions
  • On Dec. 7, 2021, Alvotech entered into a definitive business combination agreement with Oaktree & combined company’s securities are expected to be traded on NASDAQ under the symbol “ALVO”, following the completion of the transaction

Ref: Businesswire | Image: Alvotech

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions